News | January 09, 2025
GEON Performance Solutions acquires Foster Corporation
Acquisition expands high-value medical platform
Acquisition expands high-value medical platform
This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion
Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries
Consequent to this appointment, Sarosh Shetty ceases to be Interim CEO of ICH.
Nadda chairs Joint Strategy Meeting with Line Ministries for TB Mukt Bharat Abhiyan- 100-Day Intensified Campaign
These three NDAs of Sitagliptin (base) and combination franchise have been approved by the USFDA earlier through the 505(b)(2) route
The biosimilar Ustekinumab has been developed and manufactured by the company
40th DSIR Foundation Day celebration marks 16 more technology transfers from CSIR to MSMEs
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
Subscribe To Our Newsletter & Stay Updated
